EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta1

Ensembl ID : ENSPSNG00000003559
Gene Symbol: GABRB1
3 Cross references
102 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta2

Ensembl ID : ENSPSNG00000012557
Gene Symbol: GABRB2
3 Cross references
275 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta3

Ensembl ID : ENSPSNG00000007853
Gene Symbol: GABRB3
3 Cross references
263 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Delta

Ensembl ID : ENSPSNG00000001887
Gene Symbol: GABRD
3 Cross references
193 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Epsilon

Ensembl ID : ENSPSNG00000015863
Gene Symbol: GABRE
3 Cross references
109 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma1

Ensembl ID : ENSPSNG00000003406
Gene Symbol: GABRG1
3 Cross references
188 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2

Ensembl ID : ENSPSNG00000011387
Gene Symbol: GABRG2
3 Cross references
207 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSPSNG00000007646
Gene Symbol: GABRG3
3 Cross references
254 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Pi

Ensembl ID : ENSPSNG00000008024
Gene Symbol: GABRP
3 Cross references
124 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Theta

Ensembl ID : ENSPSNG00000016303
Gene Symbol: GABRQ
3 Cross references
87 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSPSNG00000017765
Gene Symbol: GABBR1
3 Cross references
264 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 2

Ensembl ID : ENSPSNG00000010007
Gene Symbol: GABBR2
3 Cross references
240 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).